Ontology highlight
ABSTRACT:
SUBMITTER: Jang J
PROVIDER: S-EPMC5800871 | biostudies-literature | 2017 Aug
REPOSITORIES: biostudies-literature
European journal of medicinal chemistry 20170503
The mutational activations of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) are validated oncogenic events and the targets of approved drugs to treat non-small cell lung cancer (NSCLC). Here we report highly potent dual small molecule inhibitors of both ALK and EGFR, particularly the T790M mutant which confers resistance to first generation EGFR inhibitors. Dual ALK/EGFR inhibitors may provide an efficient approach to prevent resistance that arises as a consequence ...[more]